These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16878308)

  • 1. Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T.
    Weidensteiner C; Rausch M; McSheehy PM; Allegrini PR
    J Magn Reson Imaging; 2006 Sep; 24(3):646-56. PubMed ID: 16878308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.
    Ceelen W; Smeets P; Backes W; Van Damme N; Boterberg T; Demetter P; Bouckenooghe I; De Visschere M; Peeters M; Pattyn P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1188-96. PubMed ID: 16457965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
    Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
    NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
    Livramento JB; Weidensteiner C; Prata MI; Allegrini PR; Geraldes CF; Helm L; Kneuer R; Merbach AE; Santos AC; Schmidt P; Tóth E
    Contrast Media Mol Imaging; 2006; 1(1):30-9. PubMed ID: 17193598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.
    Braren R; Curcic J; Remmele S; Altomonte J; Ebert O; Rummeny EJ; Steingoetter A
    Invest Radiol; 2011 Oct; 46(10):624-31. PubMed ID: 21577121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
    Park HS; Han JK; Lee JM; Kim YI; Woo S; Yoon JH; Choi JY; Choi BI
    Korean J Radiol; 2015; 16(5):1029-37. PubMed ID: 26357497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.
    Delrue LJ; Casneuf V; Van Damme N; Blanckaert P; Peeters M; Ceelen WP; Duyck PC
    MAGMA; 2011 Aug; 24(4):225-32. PubMed ID: 21567161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
    Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
    Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors.
    Baudelet C; Cron GO; Gallez B
    Magn Reson Med; 2006 Nov; 56(5):1041-9. PubMed ID: 16986109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
    Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
    NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
    Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
    Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
    Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.
    Øvrebø KM; Ellingsen C; Hompland T; Rofstad EK
    Acta Oncol; 2013 Apr; 52(3):604-11. PubMed ID: 22671573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized time-resolved imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models.
    Haeck J; Bol K; Bison S; van Tiel S; Koelewijn S; de Jong M; Veenland J; Bernsen M
    Contrast Media Mol Imaging; 2015; 10(6):413-20. PubMed ID: 25995102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI.
    Hectors SJ; Jacobs I; Lok J; Peters J; Bussink J; Hoeben FJ; Keizer HM; Janssen HM; Nicolay K; Schabel MC; Strijkers GJ
    Cancer Res; 2018 Mar; 78(6):1561-1570. PubMed ID: 29317433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gradient-echo and steady-state free precession for coronary artery magnetic resonance angiography using a gadolinium-based intravascular contrast agent.
    Deshpande VS; Cavagna F; Maggioni F; Schirf BE; Omary RA; Li D
    Invest Radiol; 2006 Mar; 41(3):292-8. PubMed ID: 16481912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.